Sunmin Lee

Also affiliated with National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 18 papers — median percentile 0. Top paper: “Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress”.

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

Cancer Cell(2021)10.1016/j.ccell.2021.02.014

N/A

4.8DataRank · unranked

178 citations

Nobuyuki Takahashi, Vinodh N. Rajapakse, Xiaohu Zhang, Yilun Sun, Michele Ceribelli +36 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3

N/A

3.0DataRank · unranked

89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma

JAMA Oncology(2021)10.1001/jamaoncol.2021.3971

N/A

1.3DataRank · unranked

45 citations

Elizabeth Hill, Alexander Dew, Candis Morrison, Joseph Roswarski, Neha Korde +29 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3305

N/A

0.725DataRank · unranked

125 citations

Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich +15 more

Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies

Translational Lung Cancer Research(2021)10.21037/tlcr-21-1

N/A

0.611DataRank · unranked

12 citations

Julie A. Hong, Tricia Kunst, Colleen D. Bond, Cara M. Kenney, Cheryl L. Warga +11 more

Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0536

N/A

0.557DataRank · unranked

40 citations

Nobuyuki Takahashi, Cody J. Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas +30 more

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

The Oncologist(2023)10.1093/oncolo/oyad164

N/A

0.512DataRank · unranked

12 citations

Yoshimi Endo Greer, Sarah M. Jenkins, Margaret E. Gatti‐Mays, Nicole Houston, Sunmin Lee +11 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3

N/A

0.507DataRank · unranked

9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15017

N/A

0DataRank · unranked

1 citations

Cody J. Peer, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Shraddha Rastogi +10 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1

N/A

0DataRank · unranked

0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1

N/A

0DataRank · unranked

0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3051

N/A

0DataRank · unranked

4 citations

Mehwish Ahmad, Guillaume Joe Pegna, Cody J. Peer, Jane B. Trepel, Min-Jung Lee +9 more

Emulsion adjuvant-induced uric acid release modulates optimal immunogenicity by targeting dendritic cells and B cells 3384

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1195

N/A

0DataRank · unranked

0 citations

Junghwa Lee, Dong‐In Kim, Eui Ho Kim, Sunmin Lee

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

Expert Opinion on Investigational Drugs(2020)10.1080/13543784.2021.1863947

N/A

0DataRank · unranked

10 citations

Yusuke Tomita, Akira Yuno, Sunmin Lee, Nacer Abrouk, Bryan Oronsky +3 more

Sunmin Lee

Indexed papers

Top data-sharing exemplar

Papers